Zoom Logo

Social & Science Special Series: After COVID-19: Anticipating Needs for Respiratory & Neuromuscular Rehabilitation - Shared screen with speaker view
Gordon Mitchell
36:48
Please feel free to fire questions on the board and we will address them in the gap between speakers!
David Fuller
37:52
what is standard of care currently? what drugs are being given?
Ela Sajjadi
43:02
The opacity of the lung seems to change in X-ray images of the lungs of the COVID patients, how does that affect the compliance? since you mentioned that lung compliance is normal?
David Fuller
45:00
what do we make of the BMI data? does obesity impair lung mechanics...or?
Emily Fox
45:14
what are the responses to these drug therapies and are there long term implications of these drugs?
Branden Nguyen
47:40
One of the data tables showed 44% patients with hypertension, Do you think patients on antihypertensive drugs could impact patient outcomes?
Juliana Burt
47:57
What is the general consenus at UFHealth regarding the mechanism of action of the virus? Or is there a general consenus at all?
THIERRY PEREZ
51:42
In your experience what is the frequency of mismatch between dyspnea intensity and hypoxemia or marked pulmonary infiltrates ?
David Fuller
53:51
thank you so much for this presentation. We appreciate your time and expertise!
Emily Fox
54:09
thank you!!
David Fuller
01:13:42
Paul - could the “happy hypoxemic” covid patient have an impaired carotid body (cytokines) or an impaired central “gate” so that signals are not reaching the sensory cortex?
Alfredo J Garcia III
01:23:28
Any thoughts on prevalence of sleep apnea in these patients?
Shakeel Ahmed
01:27:57
Dr . Davenport : Do patients with “prior experience “ of dyspnea due to a pre existing respiratory disease have lower thresholds to perceive dyspnea when affected by a newer disease? Do they have a stronger affective component?
Alfredo J Garcia III
01:29:44
Has either UF or UW adopted using noninvasive helmets for high flow?
Jorge Lascano
01:29:45
how does cytokines (IL-6) affect carotid receptors. ?
Jorge Lascano
01:30:32
We could cross analyzed data as we have levels of Il-6 in a significant number of patients
Shakeel Ahmed
01:30:58
Thanks
Ashley Ross
01:31:11
Thanks!
jfeinstein
01:33:56
Has anyone had any luck administering IL-6 inhibitors?
Alfredo J Garcia III
01:36:13
Thank you!
David Fuller
01:36:25
thanks!
Yasin Seven
01:36:29
Thank you!!
Wendy Olsen
01:36:32
Thank you!!
Fer
01:36:34
Thank you!
bksmith@ufl.edu
01:36:41
terrific- thank you!
THIERRY PEREZ
01:36:51
Stimulating data and hypothesis
Terence Ryan
01:37:01
Thank you!
Jyoti Watters
01:37:04
Thank you!